ReviewNanomaterials (Basel, Switzerland)2026
Nanotoxicology: Emerging Challenges and Future Solutions for Safe Nanomaterial Applications.
Review in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of nanotechnology has led to a rapid increase in intentional and unintentional exposure to engineered nanoparticles (NPs), raising significant concerns over their impact on humans, animals, and ecosystems. Nanotoxicology has evolved to assess these adverse effects, but the field faces key challenges including complex physicochemical characterization, difficulties in exposure assessment, dynamic biological interactions, and distinct regulatory gaps. To address these challenges, solutions such as the standardization of testing protocols, the adoption of advanced 3D in vitro and in silico modeling, and the implementation of "safer-by-design" principles are proposed. The development of biodegradable nanomaterials (NMs) and effective risk management further emphasizes that responsible development and interdisciplinary collaboration are essential to balance technological innovation with human and environmental safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.